↩ Compound referenceGrowth Hormone Releasing

NAD+

100mg500mg1,000mg
Reported, not recommended

Every figure below is transcribed from published literature (peptideprotocolportal.com, compiled 2026-09-29). None of it is a recommendation, a protocol, or a target, and none of it was written here. Whether any of it applies to a person is a question for a licensed clinician — who this is for explains why.

What the source says not to do

Quoted word for word from the notes column. Nothing here is paraphrased, and nothing has been added.

  • Single dose not to exceed 250mg
  • IM single dose not to exceed 250mg.

All 3 presentations, as reported

The source lists this compound once per vial size. All of them are shown rather than one chosen for you, because the ranges differ between them.

Reported dose, frequency and route for NAD+, by vial size.
VialDoseFrequencyRoute
100mg50-100mgDaily or 2x/weekIM
500mg50-150mgDaily or 2x/weekIM
1,000mg100-250mgDaily or 2x/weekIM/IV

The source's own notes

Reproduced in full, including the parts that are description rather than caution. Trimming this column for layout would remove its harm-reduction payload.

Single dose not to exceed 250mg

High-volume vial for IV drip protocols - dilute in NS/D5W. IM single dose not to exceed 250mg. IV: 500-1,000mg over 2-4 hrs


Before anything else

A compound's paperwork is the part you can actually verify. Reading a Certificate of Analysis and what a COA cannot tell you cover both halves of that, and inspecting a vial on arrival covers what to check before a vial is opened at all.